

DYNAMK

— CAPITAL —

Funding the Future of Life Sciences™

Investing In

Growth and Early Stage
companies developing
novel life science tools
technologies and services

Expertise In

The toughest issues facing
start-ups: launch, scaling
revenues, strategic moves
and positioning for exit

Succeed By

Extending decades of industry
operating and business expe-
rience along with access to a
first-class network

www.dynamk.vc

More than a team, an entire network

We understand entrepreneurs because we are entrepreneurs. Dynamk works side by side with management teams to identify and execute growth opportunities. We leverage our network of domain and subject matter experts to cultivate collaborative partnerships and develop exit pathways.

Our Team

Our team has decades of experience as life science entrepreneurs, advisors, corporate executives and board directors. We are passionate about accelerating the growth of our portfolio businesses.

We've created over \$3B
in value for startups and
corporates

Dynamk team members
have led over 140
transactions



Daniella Kranjac,
ChEng, MBA
Founding Partner



Dr. Gustavo Mahler,
Ph.D., MBA
Managing Partner



Mario M. Kranjac, J.D.
Founding Partner,
General Counsel



Reinhard Vogt
Venture Partner



Sebastien Latapie, MBA
Sr. Venture Associate

The Time is Now

Advances in novel therapeutics including complex biologics, vaccines, cell & gene therapies and regenerative medicine are creating the demand for novel, purpose-built tools and technologies. A.I. and machine learning, microfluidics, automation and disruptive service models are evolving faster than ever before. This convergence of technology is giving rise to new opportunities across life sciences.

We provide the fuel, resources and capital that life science entrepreneurs need.

Network/
Connections

Talent

Expertise

Strategy/
Operations

Network Connections and Building Community

Whether it's introductions to Key Opinion Leaders (KOLs), important strategic players or customers, we have a deep network of experts that we actively leverage for our portfolio companies.

[It's Who You Know](#)

Talent

Great people are not hard to find when you know where to look. We make intros to life science leaders we've worked with around the world. We help you with compensation strategies and securing the best talent.

[Finding the Best Life Science Leaders](#)

Expertise

We've worked on the toughest issues facing startups and corporates alike. Scaling revenues, making the right strategic moves, raising your next round or positioning your business for an exit, we're here to help.

[There's no Substitute for Experience](#)

Strategy Development and Operations

Understanding the big picture is critical. We support technical founders with key market intelligence and introductions to commercial leaders and strategic partners at the right time. Our experience with launch planning, marketing and commercialization are big differentiators.

[Leverage What We Learned](#)

Our Portfolio Companies

Dynamk works with entrepreneurs and innovators to accelerate start-ups in Life Science Industrials, providing fundamental technologies and services to biopharma.

Our portfolio companies are enabling the future of biotechnology, cell and gene therapies, vaccines and regenerative medicine.



DELIVERY OF GENE EDITING PAYLOADS FOR CELL AND GENE THERAPIES

CellFE is enabling the next generation of cell and gene therapies by efficiently delivering gene-editing payloads with high throughput, and preserving cell function and viability.



RNA SPLICING ANALYTICS + ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY

Envisagenics' mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence.



ACCELERATING THE USE OF STEM CELLS FOR REGENERATIVE MEDICINE

RoosterBio is accelerating the field of regenerative medicine and disrupting the market by radically simplifying human mesenchymal stem / stromal cell (hMSC) biomanufacturing and supply of critical reagents.

Exits

ACOUSTIC CELL HANDLING

FloDesign Sonics' acoustic technology is unique, disruptive, and broad-based. FDS is set to disrupt bioprocessing and immunotherapy delivery.

ACQUIRED BY MILLIPORESIGMA, OCTOBER 2019

